Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;29(1):92-3.
doi: 10.5505/tjh.2012.26539. Epub 2012 Mar 5.

Rituximab therapy for refractory autoimmune thrombocytopenia in patients with systemic lupus erythematosus

Didem Atay  1 , Gülyüz Oztürk  2 , Sema Anak  2 , Omer Devecioğlu  2 , Ayşegül Unüvar  2 , Zeynep Karakaş  2 , Leyla Ağaoğlu  2
Affiliations

Rituximab therapy for refractory autoimmune thrombocytopenia in patients with systemic lupus erythematosus

Didem Atay et al. Turk J Haematol. 2012 Mar.
No abstract available

PubMed Disclaimer

References

    1. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol. 2004;4:398–402. - PubMed
    1. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune mediated hematologic diseases. Am J Hematol. 2004;77:303–310. - PubMed
    1. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857–3861. - PubMed
    1. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S. Safety, efficacy and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50:822–825. - PubMed
    1. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–2642. - PMC - PubMed

LinkOut - more resources